Purchase this article with an account.
Giulia Caminiti, Riccardo Saldì, Giovanni M. Satta, Beatrice Lobina, Enrico Peiretti; Anti-vegf Theraphy Versus Pdt in the Treatment of Cnv Secondary to Crsc. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2149.
Download citation file:
© 2017 Association for Research in Vision and Ophthalmology.
To describe a consecutive series of patients affected by chronic central serous chorioretinopathy (CRSC) complicated with choroidal neovascularization (CNV) treated with intravitreal injection (IVT) of anti-VEGF or photodynamic therapy (PDT).
40 eyes of 34 consecutive patients have been followed for a minimum of 1 year and maximum of 7 years with an history of CRSC complicated with CNV. All the patients were evaluated with fluorescein, indocyanine angiography (FA, ICG) and OCT scan that revealed polypoidal lesions in 67% of the CNV. Patients were classified in 3 groups: the first group included 18 eyes treated with photodynamic therapy (PDT), the second group comprised 19 eyes treated with intravitreal injection (IVT) of anti-VEGF (Bevacizumab, Pegaptanib or Ranibizumab) and the third group involved 3 eyes treated with combination therapy (PDT + IVT). Each patient performed FA, ICG and OCT at the baseline and during the follow-up depending on the physician discretion. The fixed schedule for the follow-up was every 3 months for PDT, after 1,2 and 3 months for the IVT patients with a chance to extend the fixed visit to a maximum of 6 months. The third group had a follow-up similar to the first group.
After 1 year of follow-up, the first group (only PDT) showed that 64% of the eyes had an improvement of best corrected visual acuity (BCVA), the 21% had stabilization and the remaining 15% had a worsening of VA, with a mean of 1.5 PDT sessions. In the second group of patients (IVT of anti-VEGF) 47% of the eyes had an improvement of BCVA, 33% had stabilization and 20% showed a reduction of VA, the mean average of IVT was 3.3. In third group of patients (PDT + IVT) 33% increased his BCVA, 33% no change and 33% had a reduction of BCVA, each patient performed a mean of 1.5 sessions of combination therapy.
Similarly, IVT of anti-VEGF and Photodynamic therapy as well, demonstrated to be efficacy in maintaining or improving BCVA in more than 65% of patients with CRSC complicated with CNV.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only